As I mentioned, we have a candidate therapy for the treatment of prostate cancer in Phase II clinical trials. The prostate cancer drug has a promising safety profile and exhibits good oral bioavailability. As reported at the recent American Association of Cancer Researchers meeting, our drug was given to men with advanced prostate cancer, who had relapsed and had dramatically increasing PSA levels. When the drug is approved by the FDA, we will sell it through our existing oncology sales force. Myriad has an existing oncology sales force of over 60 sales people calling on all of the cancer centers and all of the oncologists in the United States.
Myriad is unique in a couple of respects in comparison to other genomic and proteomic companies.
First of all, we actually sell products and have re curring product revenue. Myriad has shown not only that it can discover a gene and determine the function of the protein produced by that gene, but more importantly that it can turn the discovery into a product, build a sales force, and sell that product successfully with attractive margins and attractive revenue growth rates. The other area that differentiates our company is our technology. We practice an integrated proteomics strategy. We don t rely on a single technology but apply five complementary technologies in an automated, industrialized, high-throughput manner.